Evidence map›Paper›PMID 33392617›Full record

ArticleJournal of radiation research2021

Capacity of proton beams in preserving normal liver tissue during proton beam therapy for hepatocellular carcinoma.

Yu-Lun Tsai, Hideyuki Takei, Takashi Iizumi, Toshiyuki Okumura, Yuta Sekino, Haruko Numajiri, Hitoshi Ishikawa, Takeji Sakae, Hideyuki Sakurai

Open access · goldAbstract read
In one paragraph

Article in Journal of radiation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Yu-Lun TsaiDepartment of Radiation Oncology, Cathay General Hospital, Taipei, Taiwan.
Hideyuki TakeiProton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Takashi IizumiProton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Toshiyuki OkumuraProton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Yuta SekinoProton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Haruko NumajiriProton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Hitoshi IshikawaProton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Takeji SakaeProton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Hideyuki SakuraiProton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan.
University of Tsukuba · JPCathay General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unirradiated liver volume (ULV) preservation rate is an important factor associated with radiation-induced liver disease (RILD) in patients with hepatocellular carcinoma (HCC) undergoing proton beam therapy (PBT). The purpose of this study is to identify the predictors for ULV preservation and quantify the capacity of proton beams in normal liver sparing during PBT. We reviewed planning data of 92 patients with single intrahepatic HCC tumors undergoing PBT. The potential clinical and planning factors that may affect ULV preservation were involved in multiple linear regression for ULV preservation rate. The significant factors were determined to be predictors and their influences were quantified. The median ULV preservation rate was 62.08%. All the assessed clinical factors showed significant effects on ULV preservation rate: clinical target volume (CTV), P < 0.001; portal vein tumor thrombosis (PVTT), P = 0.010; left lobe tumor, P = 0.010. In contrast, none of the planning factors demonstrated significance. The coefficients of significant factors in multiple linear regression were 60.85 for intercept, -0.02 for CTV, -9.01 for PVTT and 8.31 for left lobe tumors. The capacity of proton beams to spare normal liver tissue during PBT for HCC is mainly affected by clinical factors. The baseline of the ULV preservation rate is 60.85%, decreasing 0.02% with each milliliter of CTV increase and 9.01% for tumors with PVTT, and increasing 8.31% for tumors limited to the left lobe. Further clinical studies should be carried out to correlate our dosimetric findings with clinical outcomes.

Indexed as

ProtonsProton TherapyCarcinoma, HepatocellularHumansLiverLiver NeoplasmsOrgan SizeRadiotherapy Planning, Computer-AssistedReproducibility of ResultsProtonshepatocellular carcinomanormal liver sparingproton beam therapyunirradiated liver volume

Identifiers

PMID33392617
PMCPMC7779355
OpenAlexW3097220894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.